STOCKSCREENR
Log In

INM

NASDAQ

InMed Pharmaceuticals Inc.

$0.89+0.03(+3.30%)Mkt Cap: $1.61M

Key Stats

Market Cap

$1.61M

P/E Ratio

-0.31

EPS

$-2.88

Dividend Yield

0.00%

52-Week Range

$0.73 — $7.98

Volume

120.07K

Avg Volume

88.23K

Beta

0.46

Valuation

P/E (TTM)

-0.31

Forward P/E

—

PEG Ratio

0.00

P/S (TTM)

0.32

P/B (TTM)

0.00

P/FCF

—

EV/EBITDA

—

EV/Sales

—

Financial Health

ROE (TTM)

-0.63%

ROA (TTM)

-0.59%

ROIC

—

Gross Margin

0.26%

Operating Margin

-1.75%

Net Margin

—

Debt/Equity

0.06

Current Ratio

5.94

Growth

EPS Growth (YoY)

—

Revenue Growth (YoY)

—

EPS Growth (3Y)

+0.75%

EPS Growth (5Y)

-3.86%

Sales Growth (3Y)

+0.99%

Sales Growth (5Y)

+0.60%

EPS Est (This Year)

$0.00

EPS Est (Next Year)

—

Dividends

Dividend Yield

—

Annual Dividend

—

Payout Ratio

—

Frequency

—

Ex-Dividend Date

—

Cash/Share

$2429.08

Ownership

Institutional %

—

Inst. Net Change

—

Insider Net Shares (90d)

0

Outstanding Shares

1.81M

Float

1.80M

Free Float %

99.61%

About

Sector

Healthcare

Industry

Biotechnology

Country

CA

Exchange

NASDAQ

IPO Date

2014-05-05

Employees

13

CEO

Eric A. Adams Chem.

Index Membership

—

Website

https://www.inmedpharma.com

InMed Pharmaceuticals Inc. (INM) is a healthcare company in the biotechnology industry listed on the NASDAQ. With a market capitalization of $1.61M, a P/E ratio of -0.31, INM is tracked by stockscreenr alongside 25,000+ other tickers. Use the free stock screener to compare INM against other stocks using dozens of fundamental and technical filters.

Similar Stocks

APS.TO

Aptose Biosciences Inc.

$2.22

+1.37%

$5.67M

IBO.V

Universal Ibogaine Inc.

$0.01

-50.00%

$1.56M

IMRN

Immuron Limited

$0.75

-5.19%

$4.83M

ASBP

Aspire Biopharma Holdings, Inc.

$0.88

-10.21%

$3.03M

BRTX

BioRestorative Therapies, Inc.

$0.25

-12.40%

$2.24M

CARM

Carisma Therapeutics, Inc.

$0.04

+2.70%

$1.59M

Frequently Asked Questions

What is InMed Pharmaceuticals Inc.'s P/E ratio?

InMed Pharmaceuticals Inc. (INM) has a trailing twelve-month (TTM) P/E ratio of -0.31. This is below the market average, which may suggest the stock is undervalued or has lower growth expectations. The P/E ratio measures how much investors are willing to pay per dollar of earnings.

Does InMed Pharmaceuticals Inc. pay a dividend?

No, InMed Pharmaceuticals Inc. (INM) does not currently pay a regular dividend. The company may be reinvesting profits into growth, research, or debt reduction instead of returning cash to shareholders through dividends.

What is InMed Pharmaceuticals Inc.'s market cap?

InMed Pharmaceuticals Inc. (INM) has a market capitalization of $1.61 million, classifying it as a micro-cap company. Market cap is calculated by multiplying the current share price by the total number of outstanding shares.